雷公藤在大鼠1型糖尿病模型中对调节性T细胞Foxp3表达的影响及意义

《雷公藤在大鼠1型糖尿病模型中对调节性T细胞Foxp3表达的影响及意义》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、雷公藤在大鼠1型糖尿病模型中对调节性T细胞Foxp3表达的影响及意义【摘要】　　目的:研究雷公藤在大鼠1型糖尿病模型中对CD4+CD25+调节性T细胞（Tr）Foxp3基因表达的影响及意义。方法:将48只大鼠随机分为3组,每组各16只,Ⅱ、Ⅲ组采用小剂量多次腹腔注射链脲佐菌素（STZ）的方法制备大鼠1型糖尿病模型,Ⅰ组为正常对照。Ⅲ组在成模后给与雷公藤多甙（GTT）灌胃,1次/d,连续3个月。淋巴细胞转化试验（MTT法）检测脾淋巴细胞增殖活性;荧光定量PCR检测外周血及脾淋巴细胞Foxp3mRNA的表达;免疫组化检测淋巴结和

2、脾组织FOXP3蛋白的表达。结果:Ⅱ、Ⅲ组血糖水平高于Ⅰ组（P<0.01）;胰岛中Ⅲ组淋巴细胞浸润程度较Ⅱ组减轻;Ⅱ、Ⅲ组淋巴细胞增殖活性均较Ⅰ组升高（P<0.01）,用药后Ⅲ组较Ⅱ组降低;Foxp3mRNA、FOXP3蛋白表达水平Ⅱ、Ⅲ组均高于Ⅰ组（P<0.05）,Ⅲ组表达水平较Ⅱ组有所升高,但差别无统计学意义（P>0.05）。结论:Foxp3+Tr细胞参与了STZ诱导的大鼠1型糖尿病的发生发展;上调Tr细胞Foxp3基因的表达可能为雷公藤治疗1型糖尿病的机制之一。【关键词】CD4+CD25+调节性

3、T细胞Foxp3雷公藤1型糖尿病　　[Abstract]AIM:ToinvestigatethesignificanceandeffectofGlucosidorumTripterygiitororum(GTT)onthe13expressionsofFoxp3inCD4+CD25+regulatoryTcells（Tr）intype1diabeticratmodel.METHODS:48ratsweredividedevenlyinto3groupsbyrandom.Diabeticmodelwasdevelopedbym

4、ultiplelowdoseintraperitonealinjectionofstreptozotociningroupⅡ,Ⅲ,andgroupⅠwastreatedasnormalcontrol.Aftertheestablishmentofthemodel,administrationofGTTwasconductedingroupⅢ,whichwasperformedonceaday,lastingthreemonthes.Lymphocyteproliferationwasdetectedbylymphocytet

5、ransformationtest（MTTassay）.TheexpressionofFoxp3mRNAwasmeasuredinperipheralbloodandspleenbyusingrealtimePCR.TheexpressionofFoxp3proteininlymphoidnodeandspleenwasdetectedbyimmunohistochemistry.RESULTS:ThebloodglucoselevelingroupⅡ,Ⅲwasobviouslyhigherthanthatofcontro

6、lgroup（P<0.01）,followedwithlymphocyteinfiltratinginpancreaticislets.TheinfiltratingdegreeingroupⅢwasdecreasedthanthatofgroupⅡ.TheproliferationofspleniclymphocyteingroupⅡ,Ⅲwasevidentlyincreasedcomparingwiththecontrolgroup(P<0.01).AfteradministrationofGTT,thepr

7、oliferationingroupⅢwaslowerthanthatingroupⅡ.IngroupⅡ,Ⅲ,theexpressionsofFoxp3mRNAandproteinincreasedmarkedlycomparedwithcontrolgroup（P<0.05）.Moreover,thelevelingroupⅢwasespecially13enhanced,butcomparedwithgroupⅡ,therewasnosignificantlydifference(P>0.05).CONCLU

8、SION:Foxp3+Trmayinvolveinthepathogenesyoftype1diabetesindusedbySTZ.GTTdidhavetherapeuticaleffectontype1diabetes,possiblythroughupregulatingtheexp